Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Apr;108(4):927–932. doi: 10.1111/j.1476-5381.1993.tb13488.x

Alpha 2-adrenoceptor antagonist potencies of two hydroxylated metabolites of yohimbine.

M Berlan 1, R Le Verge 1, J Galitzky 1, P Le Corre 1
PMCID: PMC1908160  PMID: 8097957

Abstract

1. The alpha 2-adrenoceptor antagonist capacities of two hydroxylated metabolites of yohimbine in man (10-OH-yohimbine and 11-OH-yohimbine) were investigated on the alpha 2-adrenoceptors of human platelets and adipocytes and compared to those of yohimbine. 2. Yohimbine and 11-OH-yohimbine exhibited similar alpha 2-adrenoceptor affinity in biological studies i.e. inhibition of adrenaline-induced platelet aggregation and inhibition of UK14304-induced antilipolysis in adipocytes. 3. Yohimbine and the two metabolites displaced [3H]-RX 821002 binding with equivalent affinities in platelet and adipocyte membranes with the following order of potency: yohimbine > 11-OH-yohimbine > 10-OH-yohimbine. However, when binding studies were carried out in binding buffer supplemented with 5% albumin, the apparent affinity of yohimbine was reduced about 10 fold and was similar to that of 11-OH-yohimbine. 4. Yohimbine and its metabolites were bound to different extents to plasma proteins, the bound fraction being 82%, 43% and 32% respectively for yohimbine, 11-OH-yohimbine and 10-OH-yohimbine. 5. These results show that the main hydroxylated metabolite of yohimbine in man (11-OH-yohimbine) possesses alpha 2-adrenoceptor antagonist properties. The discrepancies found in binding studies (i.e. 10 fold lower affinity of 11-OH-yohimbine than yohimbine for alpha 2-adrenoceptors but similar capacities in blocking biological alpha 2-adrenoceptor effects in cells) are attributable to the higher degree of binding of yohimbine to plasma protein.

Full text

PDF
927

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berlan M., Galitzky J., Riviere D., Foureau M., Tran M. A., Flores R., Louvet J. P., Houin G., Lafontan M. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women. Int J Obes. 1991 May;15(5):305–315. [PubMed] [Google Scholar]
  2. Berlin I., Crespo-Laumonnier B., Turpin G., Puech A. J. The alpha-2 adrenoceptor antagonist yohimbine does not facilitate weight loss but blocks adrenaline induced platelet aggregation in obese subjects. Therapie. 1989 Jul-Aug;44(4):301–301. [PubMed] [Google Scholar]
  3. Brannan T., Martinez-Tica J., Yahr M. D. Effect of yohimbine on brain monoamines: an in vivo study. J Neural Transm Park Dis Dement Sect. 1991;3(2):81–87. doi: 10.1007/BF02260883. [DOI] [PubMed] [Google Scholar]
  4. Charney D. S., Price L. H., Heninger G. R. Desipramine-yohimbine combination treatment of refractory depression. Implications for the beta-adrenergic receptor hypothesis of antidepressant action. Arch Gen Psychiatry. 1986 Dec;43(12):1155–1161. doi: 10.1001/archpsyc.1986.01800120041009. [DOI] [PubMed] [Google Scholar]
  5. Galitzky J., Larrouy D., Berlan M., Lafontan M. New tools for human fat cell alpha-2A adrenoceptor characterization. Identification on membranes and on intact cells using the new antagonist [3H]RX821002. J Pharmacol Exp Ther. 1990 Jan;252(1):312–319. [PubMed] [Google Scholar]
  6. Galitzky J., Senard J. M., Lafontan M., Stillings M., Montastruc J. L., Berlan M. Identification of human platelet alpha 2-adrenoceptors with a new antagonist [3H]-RX821002, a 2-methoxy derivative of idazoxan. Br J Pharmacol. 1990 Aug;100(4):862–866. doi: 10.1111/j.1476-5381.1990.tb14105.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Galitzky J., Taouis M., Berlan M., Rivière D., Garrigues M., Lafontan M. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers. Eur J Clin Invest. 1988 Dec;18(6):587–594. doi: 10.1111/j.1365-2362.1988.tb01272.x. [DOI] [PubMed] [Google Scholar]
  8. Goldberg M. R., Hollister A. S., Robertson D. Influence of yohimbine on blood pressure, autonomic reflexes, and plasma catecholamines in humans. Hypertension. 1983 Sep-Oct;5(5):772–778. doi: 10.1161/01.hyp.5.5.772. [DOI] [PubMed] [Google Scholar]
  9. Goldberg M. R., Robertson D. Yohimbine: a pharmacological probe for study of the alpha 2-adrenoreceptor. Pharmacol Rev. 1983 Sep;35(3):143–180. [PubMed] [Google Scholar]
  10. Grunhaus L., Tiongco D., Zelnik T., Flegel P., Hollingsworth P. J., Smith C. B. Intravenous yohimbine. Selective enhancer of norepinephrine and cortisol secretion and systolic blood pressure in humans. Clin Neuropharmacol. 1989 Apr;12(2):106–114. doi: 10.1097/00002826-198904000-00004. [DOI] [PubMed] [Google Scholar]
  11. Guthrie S. K., Hariharan M., Grunhaus L. J. Yohimbine bioavailability in humans. Eur J Clin Pharmacol. 1990;39(4):409–411. doi: 10.1007/BF00315421. [DOI] [PubMed] [Google Scholar]
  12. Lambert G. A., Lang W. J., Friedman E., Meller E., Gershon S. Pharmacological and biochemical properties of isomeric yohimbine alkaloids. Eur J Pharmacol. 1978 May 1;49(1):39–48. doi: 10.1016/0014-2999(78)90220-0. [DOI] [PubMed] [Google Scholar]
  13. Le Verge R., Le Corre P., Chevanne F., Döe De Maindreville M., Royer D., Levy J. Determination of yohimbine and its two hydroxylated metabolites in humans by high-performance liquid chromatography and mass spectral analysis. J Chromatogr. 1992 Feb 14;574(2):283–292. doi: 10.1016/0378-4347(92)80041-n. [DOI] [PubMed] [Google Scholar]
  14. Mauriege P., Galitzky J., Berlan M., Lafontan M. Heterogeneous distribution of beta and alpha-2 adrenoceptor binding sites in human fat cells from various fat deposits: functional consequences. Eur J Clin Invest. 1987 Apr;17(2):156–165. doi: 10.1111/j.1365-2362.1987.tb02395.x. [DOI] [PubMed] [Google Scholar]
  15. Onrot J., Goldberg M. R., Biaggioni I., Wiley R. G., Hollister A. S., Robertson D. Oral yohimbine in human autonomic failure. Neurology. 1987 Feb;37(2):215–220. doi: 10.1212/wnl.37.2.215. [DOI] [PubMed] [Google Scholar]
  16. Owen J. A., Nakatsu S. L., Fenemore J., Condra M., Surridge D. H., Morales A. The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol. 1987;32(6):577–582. doi: 10.1007/BF02455991. [DOI] [PubMed] [Google Scholar]
  17. Peskind E. R., Veith R. C., Dorsa D. M., Gumbrecht G., Raskind M. A. Yohimbine increases cerebrospinal fluid and plasma norepinephrine but not arginine vasopressin in humans. Neuroendocrinology. 1989 Sep;50(3):286–291. doi: 10.1159/000125235. [DOI] [PubMed] [Google Scholar]
  18. Rispail Y., Schmitt L., Berlan M., Montastruc J. L., Montastruc P. Yohimbine increases salivary secretion in depressed patients treated with tricyclic antidepressants. Eur J Clin Pharmacol. 1990;39(4):425–426. doi: 10.1007/BF00315426. [DOI] [PubMed] [Google Scholar]
  19. Villeneuve A., Berlan M., Lafontan M., Caranobe C., Boneu B., Rascol A., Montastruc J. L. Platelet alpha 2 adrenoceptors in Parkinson's disease: decreased number in untreated patients and recovery after treatment. Eur J Clin Invest. 1985 Dec;15(6):403–407. doi: 10.1111/j.1365-2362.1985.tb00292.x. [DOI] [PubMed] [Google Scholar]
  20. WIELAND O. Eine enzymatische Methode zur Bestimmung von Glycerin. Biochem Z. 1957;329(4):313–319. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES